Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
146 JPY | -2.67% | -5.19% | -31.13% |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 6,322 | - | - |
Enterprise Value (EV) 1 | 6,322 | 6,322 | 6,322 |
P/E ratio | -7.63 x | -7.4 x | -7.18 x |
Yield | - | - | - |
Capitalization / Revenue | 19.8 x | 19.8 x | 19.8 x |
EV / Revenue | 19.8 x | 19.8 x | 19.8 x |
EV / EBITDA | -7.44 x | -7.22 x | -6.99 x |
EV / FCF | - | - | - |
FCF Yield | - | - | - |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 43,302 | - | - |
Reference price 2 | 150.0 | 150.0 | 150.0 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | 625.8 | 319 | 319 | 319 |
EBITDA 1 | - | -850 | -876 | -904 |
EBIT 1 | - | -849.5 | -876.2 | -904 |
Operating Margin | - | -266.3% | -274.67% | -283.39% |
Earnings before Tax (EBT) 1 | - | -850 | -876 | -904 |
Net income 1 | -386.6 | -851 | -877 | -905 |
Net margin | -61.78% | -266.77% | -274.92% | -283.7% |
EPS 2 | - | -19.65 | -20.27 | -20.90 |
Free Cash Flow | - | - | - | - |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 3/13/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: |
---|
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 3/13/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.13% | 41.95M | |
+7.97% | 113B | |
+10.44% | 106B | |
+0.41% | 22.27B | |
-11.92% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-4.96% | 17.24B | |
+6.63% | 14.29B | |
+36.01% | 12.52B |
- Stock Market
- Equities
- 4893 Stock
- Financials Noile-Immune Biotech Inc.